An open-label, multi-center, expanded access study of RAD001 in patients with angiomyolipoma associated with tuberous sclerosis complex (TSC)
Latest Information Update: 13 Oct 2014
At a glance
- Drugs Everolimus (Primary)
- Indications Angiomyolipoma; Tuberous sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 11 Oct 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 05 Feb 2014 New trial record